Literature DB >> 33538774

Prevalence of SARS-CoV-2 in Karnataka, India.

Manoj Mohanan1, Anup Malani2, Kaushik Krishnan3, Anu Acharya4.   

Abstract

Entities:  

Year:  2021        PMID： 33538774      PMCID： PMC7863009          DOI： 10.1001/jama.2021.0332

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  3 in total

1.  Estimating prevalence from the results of a screening test.

Authors:  W J Rogan; B Gladen
Journal:  Am J Epidemiol       Date:  1978-01       Impact factor: 4.897

2.  Universal screening identifies asymptomatic carriers of SARS-CoV-2 among pregnant women in India.

Authors:  Rakesh Waghmare; Rahul Gajbhiye; Niraj N Mahajan; Deepak Modi; Sanjay Mukherjee; Smita D Mahale
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2020-09-23       Impact factor: 2.435

3.  Comparative evaluation of SARS-CoV-2 IgG assays in India.

Authors:  Susmita Chaudhuri; Ramachandran Thiruvengadam; Souvick Chattopadhyay; Farha Mehdi; Pallavi Kshetrapal; Tripti Shrivastava; Bapu Koundinya Desiraju; Gaurav Batra; Gagandeep Kang; Shinjini Bhatnagar
Journal:  J Clin Virol       Date:  2020-08-24       Impact factor: 3.168
  3 in total
  8 in total

1.  Seroprevalence of SARS-CoV-2 infection and associated factors among Bangladeshi slum and non-slum dwellers in pre-COVID-19 vaccination era: October 2020 to February 2021.

Authors:  Rubhana Raqib; Protim Sarker; Evana Akhtar; Tarique Mohammad Nurul Huda; Md Ahsanul Haq; Anjan Kumar Roy; Md Biplob Hosen; Farjana Haque; Md Razib Chowdhury; Daniel D Reidpath; Dewan Md Emdadul Hoque; Zahirul Islam; Shehlina Ahmed; Tahmeed Ahmed; Fahmida Tofail; Abdur Razzaque
Journal:  PLoS One       Date:  2022-05-23       Impact factor: 3.752

2.  SARS-CoV-2 seroprevalence in the city of Hyderabad, India in early 2021.

Authors:  Avula Laxmaiah; Nalam Madhusudhan Rao; N Arlappa; Jagjeevan Babu; P Uday Kumar; Priya Singh; Deepak Sharma; V Mahesh Anumalla; T Santhosh Kumar; R Sabarinathan; M Santhos Kumar; R Ananthan; D Anwar Basha; P P S Blessy; D Chandra Kumar; P Devaraj; S Devendra; M Mahesh Kumar; Indrapal I Meshram; B Naveen Kumar; Paras Sharma; P Raghavendra; P Raghu; K Rajender Rao; P Ravindranadh; B Santosh Kumar; G Sarika; J Srinivasa Rao; M V Surekha; F Sylvia; Deepak Kumar; G Subba Rao; Karthik Bharadwaj Tallapaka; Divya Tej Sowpati; Surabhi Srivastava; V Manoj Murhekar; Rajkumar Hemalatha; Rakesh K Mishra
Journal:  IJID Reg       Date:  2021-11-19

3.  Seroepidemiological study of SARS-CoV-2 infection in East Java, Indonesia.

Authors:  Ni Luh Ayu Megasari; Takako Utsumi; Laura Navika Yamani; Emily Gunawan; Koichi Furukawa; Mitsuhiro Nishimura; Maria Inge Lusida; Yasuko Mori
Journal:  PLoS One       Date:  2021-05-06       Impact factor: 3.240

4.  Incorporating false negative tests in epidemiological models for SARS-CoV-2 transmission and reconciling with seroprevalence estimates.

Authors:  Rupam Bhattacharyya; Ritoban Kundu; Ritwik Bhaduri; Debashree Ray; Lauren J Beesley; Maxwell Salvatore; Bhramar Mukherjee
Journal:  Sci Rep       Date:  2021-05-07       Impact factor: 4.379

Review 5.  Seroprevalence of IgG antibodies against SARS-CoV-2 in India, March 2020 to August 2021: a systematic review and meta-analysis.

Authors:  Nuzrath Jahan; Adarsha Brahma; Muthusamy Santhosh Kumar; Bhavani Shankara Bagepally; Manickam Ponnaiah; Tarun Bhatnagar; Manoj V Murhekar
Journal:  Int J Infect Dis       Date:  2021-12-28       Impact factor: 12.074

6.  Asymptomatic SARS-COV-2 carriage and sero-positivity in high risk contacts of COVID-19 cases'.

Authors:  Ayan Kumar Das; Kailash Chandra; Mridu Dudeja; Mohd Khursheed Aalam
Journal:  Indian J Med Microbiol       Date:  2021-12-31       Impact factor: 1.347

7.  SARS-CoV-2 Seroprevalence Among Whole Blood Donors During First Wave of Covid-19 Pandemic in India.

Authors:  Srinivasa Rao Chunchu; Ushasree Ravula; Vikram Kumar Gente; Srinivas Bacchu; S Pandu Ranga Rao; Srujaleswari Mooli
Journal:  Indian J Hematol Blood Transfus       Date:  2022-01-30       Impact factor: 0.915

8.  SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination.

Authors:  Markus Hoffmann; Heike Hofmann-Winkler; Nadine Krüger; Amy Kempf; Inga Nehlmeier; Luise Graichen; Prerna Arora; Anzhalika Sidarovich; Anna-Sophie Moldenhauer; Martin S Winkler; Sebastian Schulz; Hans-Martin Jäck; Metodi V Stankov; Georg M N Behrens; Stefan Pöhlmann
Journal:  Cell Rep       Date:  2021-06-29       Impact factor: 9.423
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.